

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/831,142	05/07/2001	Anthony Keith Campbell	WCM.69.US	1038
7590 01/12/2004			EXAMINER	
Young & Thompson			LU, FRANK WEI MIN	
745 South 23rd Street Second Floor			ART UNIT	PAPER NUMBER
	Arlington, VA 22202			
			DATE MAILED: 01/12/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>4</b> 5		Application No.	Applicant(s)
		09/831,142	CAMPBELL, ANTHONY KEITH
Office Action Summary		Examiner	Art Unit
		Frank W Lu	1634
 eriod for	The MAILING DATE of this communicate Reply	tion appears on the cover sheet wi	ith the correspondence address
THE M - Extensi after SI - If the pi - If NO p - Failure - Any rep	RTENED STATUTORY PERIOD FOR AILING DATE OF THIS COMMUNICA ions of time may be available under the provisions of 3 X (6) MONTHS from the mailing date of this communication of the reply specified above is less than thirty (30) deriod for reply is specified above, the maximum statuto to reply within the set or extended period for reply will, by received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	TION. 7 CFR 1.136(a). In no event, however, may a recation. ays, a reply within the statutory minimum of thirt by statute, cause the application to become AB	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).
1)⊠ F	Responsive to communication(s) filed o	on <u>10 October 2003</u> .	
,—	•	☐ This action is non-final.	
3)□ 5	Since this application is in condition for losed in accordance with the practice	allowance except for formal matt under <i>Ex parte Quayl</i> e, 1935 C.D	ters, prosecution as to the merits is 0. 11, 453 O.G. 213.
ispositio	n of Claims		
4) <b>×</b>	Claim(s) <u>1-30</u> is/are pending in the app		consideration
	a) Of the above claim(s) <u>11-14,18-26,2</u> Claim(s) is/are allowed.	<u>28 and 30</u> is/are withdrawn from C	Consideration.
•	Claim(s) is/are rejected.		
-	Claim(s) is/are objected to.		
•	Claim(s) <u>1-10,15-17,27 and 29</u> are sub	ject to restriction and/or election r	requirement.
pplicatio	n Papers		
, <del></del>	he specification is objected to by the E		
	he drawing(s) filed on is/are: a		
	Applicant may not request that any objectio		
	Replacement drawing sheet(s) including the		
	he oath or declaration is objected to by	y the Examiner. Note the attached	d Office Action or form P1O-152.
-	nder 35 U.S.C. §§ 119 and 120		0.440(.)(1) (2)
a)∑ * Se 13)	Acknowledgment is made of a claim fo All b) Some * c) None of:  1. Certified copies of the priority do C. Certified copies of the priority do S. Copies of the certified copies of application from the International et the attached detailed Office action for the aspecific reference was included in CFR 1.78.  The translation of the foreign languations was included in the first senter foreign was included was included in the first senter foreign was included was inc	cuments have been received. cuments have been received in A the priority documents have been I Bureau (PCT Rule 17.2(a)). for a list of the certified copies not domestic priority under 35 U.S.C. In the first sentence of the specific lage provisional application has b domestic priority under 35 U.S.C.	Application No In received in this National Stage In received. In a provisional application cation or in an Application Data Sheet In the provisional application or in an Application Data Sheet In the provisional Stage
ret	erence was included in the first senter	ice of the specification of in all Ap	pphoanon Data Sheet. of Or 1.10.
ttachment(	•	A) Interview	Summary (PTO-413) Paper No(s)
I) ⊠ Notice 2) ☐ Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO		Informal Patent Application (PTO-152)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)

6) Other:

Application/Control Number: 09/831,142

Art Unit: 1634

## **DETAILED ACTION**

## Election/Restrictions

1. Applicant's election with traverse of Group I, claims 1-10, 15-17, 27, and 29 filed on October 10, 2003 is acknowledged. The traversal is on the ground(s) that "an examination of all the pending claims is believed that fails to impose an undue searching burden on the Examiner." since "applicant believes that the claim to the present invention are directed to the subject matter in which a search and examination can be completed within a narrow discipline.".

The above arguments have been fully considered and have not been found persuasive toward the withdrawal of the restriction requirement nor persuasive toward the relaxation of same such that Groups I, II, and III will be examined together. Since this case is a 371 case, searching burden argued by applicant is not the reason for the restriction. The restriction is based on "the product of Group II does not escape the prior art" (see previous office action). Therefore, the requirement for Groups II and III is still deemed proper and is made FINAL.

- 2. After carefully reviewed the restriction made by previous examiner and the claims in Group I, additional restrictions are required as following:
- 1) Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group IA, claims 1-10, 15-17, and 27, drawn to an isolated, purified recombinant nucleic acid sequence (claims 1-5), and an isolated, purified or recombinant construct (claims 6-10), a

Application/Control Number: 09/831,142

Art Unit: 1634

cell, plasmid, virus or live organism (claim 15), a vector (claim 16), a host cell (claim 17), and the use of a sequence or a protein (claim 27).

Group IB, claims 29, drawn to a method for obtaining a substantially homologous source of apopholasin.

The inventions listed as Groups IA and IB do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The claims as drawn are related to each other because of the product in claim 1, an isolated, purified recombinant nucleic acid sequence. Since an isolated, purified recombinant nucleic acid sequence recited in (b) of claim 1 is known in the art, (for example, see Baba et al., (Anal. Chem., 64, 1920-1925, 1992, see poly T in page 1922), Groups IA and IB are no longer linked by a special technical feature, because, by definition, the special technical feature must distinguish over the prior art. Without the special technical feature, the restriction for claims 1-10, 15-17, and 29 are proper.

## 2) Sequence Election Requirement

Group IA detailed above reads on patentably distinct SEQ ID Numbers. Each sequence is patentably distinct because the sequences are structurally unrelated sequences, and a further restriction is applied. Therefore, applicant must further elect a single SEQ ID NO. (See MPEP 803.04). Applicant is advised that examination will be restricted to only elected SEQ ID NO. and should not to be construed as a species election.

Application/Control Number: 09/831,142

Art Unit: 1634

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is either (703) 308-4242 or (703)305-3014.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (703) 305-1270 (before January 13, 2004) or 571-272-0746 (after January 13, 2004). The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor. Gary Benzion, can be reached on (703) 308-1119.

Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.

Frank Lu

PSA

January 7, 2003

The in